Novo Nordisk A/S NVO:NYSE

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 05/06/24 EDT

124.20

-0.39 (-0.31%)

Volume

83,220

124.59UNCH (UNCH)

Volume

3,442,041

52 week range

75.56 - 138.28

Open122.00
Day High124.64
Day Low121.78
Prev Close124.59
52 Week High138.28
52 Week High Date03/07/24
52 Week Low75.56
52 Week Low Date07/11/23

Key Stats

Market Cap561.901B
Shares Out4.51B
10 Day Average Volume4.70M
Dividend1.37
Dividend Yield1.10%
Beta0.41
YTD % Change20.43

KEY STATS

Open122.00
Day High124.64
Day Low121.78
Prev Close124.59
52 Week High138.28
52 Week High Date03/07/24
52 Week Low75.56
52 Week Low Date07/11/23
Market Cap561.901B
Shares Out4.51B
10 Day Average Volume4.70M
Dividend1.37
Dividend Yield1.10%
Beta0.41
YTD % Change20.43

RATIOS/PROFITABILITY

EPS (TTM)2.76
P/E (TTM)45.19
Fwd P/E (NTM)0.80
EBITDA (TTM)15.856B
ROE (TTM)88.07%
Revenue (TTM)33.522B
Gross Margin (TTM)84.60%
Net Margin (TTM)36.03%
Debt To Equity (MRQ)25.34%

EVENTS

Earnings Date08/07/2024(est)
Ex Div Date03/22/2024
Div Amount0.9293
Split Date-
Split Factor-

Latest On Novo Nordisk A/S

Amgen stock soars on weight loss drug progress as Novo Nordisk, Eli Lilly slideMay 3, 2024CNBC.com
Wegovy maker Novo Nordisk extends losses following first-quarter resultsMay 3, 2024CNBC.com
Stocks making the biggest moves premarket: Apple, Amgen, Cloudflare and moreMay 3, 2024CNBC.com
European markets close higher; French banks gain on profit beats as Novo Nordisk slidesMay 3, 2024CNBC.com
Novo Nordisk falls after strong Q1 results, Mizuho's Jared Holz talks what's next for the companyMay 2, 2024CNBC.com

Content From Our Affiliates

Novo Nordisk Executes Major Share Buyback8 Hours AgoTipRanks
Novo Nordisk Executives Trade Company Shares8 Hours AgoTipRanks
Amgen price target raised to $325 from $315 at BofAMay 3, 2024TipRanks
Unusually active option classes on open May 2ndMay 2, 2024TipRanks
Novo Nordisk Q1 Sales and Profit SurgeMay 2, 2024TipRanks

Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral...

Henrik Poulsen

Vice Chairman of the Board

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Maziar Doustdar

Executive Vice President - International Operations

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Douglas Langa

Executive Vice President, North America Operations

Address

Novo Alle 1

Bagsvaerd

2880

Denmark

https://www.novonordisk.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
CAH Cardinal Health Inc	98.59	UNCH	UNCH
JNJ Johnson & Johnson	148.58	UNCH	UNCH
RDY Dr Reddy's Laboratories Ltd	74.88	UNCH	UNCH
MRK Merck & Co Inc	127.57	UNCH	UNCH
ABBV AbbVie Inc	162.73	UNCH	UNCH